Skip to search formSkip to main contentSkip to account menu

Vumon

National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Teniposide
VM-26Vehem

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo.
Review
2004
Review
2004
Current development of podophyllotoxins
SummaryThe unique biological properties and therapeutic efficacy of the podophyllotoxin derivatives, Vumon (VM26, teniposide) and… 
1997
1997
The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue
Abstract After a pre-operative 1-h i.v infusion of 150 mg/m2 of teniposide (Vumon; VM26), the drug levels were determined in… 
1997
1997
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and… 
Highly Cited
1986
Highly Cited
1986
Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
Teniposide, VM-26 (Vumon), was administered in a dose of 60 mg/m2 on days 1 to 5 every third week to 36 patients with… 
1985
1985
Renal disease and digoxin immunoassays.
Infjormation provided by pharmaceuti(cal companies in respect ofhandling and disposal of cytotoxic drugs Laminar Preparation flow… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)